Elizabeth A Cairns
Biographic Data
| ID | 7450484 |
|---|---|
| NAME | Elizabeth A Cairns |
| GIVEN NAMES | Elizabeth A |
| FAMILY NAME | Cairns |
| SIGNATURE | CAIRNS E A |
| AFFILIATIONS | The University of Sydney |
| ORCID | 0000-0002-9816-4761 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-Butica, MMB-4CN-Butinaca, MDMB-4F-Butica, MDMB-4F-Butinaca and their analogs
Synthetic cannabinoid receptor agonists (SCRAs) continue to make up a significant portion new psychoactive substances (NPS) detected and seized worldwide. Due to their often potent activation of central cannabinoid receptors in vivo , use of SCRAs can result in severe intoxication, in addition to other adverse health effects. Recent detections of AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA and MDMB-4F-BUTINACA mark a continuation in the appea…
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-Fubinaca, Cumyl-Pinaca, PB-22, and XLR-11
These results suggest that while some "off-targets" could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted
Access to cannabidiol without a prescription
There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations
No prominent works on this page.
Access to cannabidiol without a prescription
There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations
Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-Butica, MMB-4CN-Butinaca, MDMB-4F-Butica, MDMB-4F-Butinaca and their analogs
Synthetic cannabinoid receptor agonists (SCRAs) continue to make up a significant portion new psychoactive substances (NPS) detected and seized worldwide. Due to their often potent activation of central cannabinoid receptors in vivo , use of SCRAs can result in severe intoxication, in addition to other adverse health effects. Recent detections of AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA and MDMB-4F-BUTINACA mark a continuation in the appea…
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-Fubinaca, Cumyl-Pinaca, PB-22, and XLR-11
These results suggest that while some "off-targets" could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted
Cannabinoid (3 works) · Cannabis and Cannabinoid Research (3 works) · Forensic Toxicology and Drug Analysis (3 works) · Pharmacology (3 works) · Synthetic cannabinoids (3 works) · Agonist (2 works) · Biochemistry (2 works) · Biology (2 works) · Cannabinoid receptor (2 works) · Cannabinoid Receptor Agonists (2 works)